Travere Therapeutics (NASDAQ:TVTX – Get Free Report) had its target price hoisted by equities researchers at Canaccord Genuity Group from $22.00 to $45.00 in a research report issued on ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at Needham ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ocugen (OCGN – Research Report) and Xilio ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on aTyr Pharma (ATYR – Research Report), Crispr Therapeutics AG ...

Fintel reports that on February 13, 2025, Scotiabank initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a Sector ...

Using a new animal model of Alzheimer’s disease, the study highlights a potential breakthrough in treatment strategies.

"TGFB2 has emerged as a master regulator of immune suppression, not just in cancer but across multiple chronic diseases,” said Dr. Trieu. "Our work on OT-101 aims to neutralize TGFB2-driven resistance ...

Vistagen Therapeutics' Q3 2025 earnings reveal progress on Phase 3 trials for social anxiety drug fasedienol, innovative therapies, and strong ...

The average of price targets set by Wall Street analysts indicates a potential upside of 67.3% in Beam Therapeutics (BEAM). While the effectiveness of this highly sought-after metric is questionable, ...

Two new studies represent a big step toward developing innovative molecular therapies capable of disrupting the ...

GH Research PLC (NASDAQ:GHRS) has received an Overweight rating from Cantor Fitzgerald, with a price target set at $14.00. The new coverage is based on the potential of GHRS's GH001, an inhaled ...